参考文献/References:
[1] HUMBERT M，KOVACS G，HOEPER M M， et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. European Respiratory Journal, 2023, 61(1): 2200879.
[2] HOEPER M M, HUMBERT M, SOUZA R, et al. A global view of pulmonary hypertension[J]. the Lancet. Respiratory Medicine, 2016, 4(4): 306-322.
[3] BANASZKIEWICZ M, GASECKA A, DAROCHA S, et al. Circulating blood-based biomarkers in pulmonary hypertension[J]. Journal of Clinical Medicine, 2022, 11(2): 383.
[4] HOJDA S E, CHIS I C, CLICHICI S. Biomarkers in pulmonary arterial hypertension[j]. Diagnostics (basel), 2022, 12(12): 3033.
[5] 苏虹, 李仕林, 王昌育, 等. 成纤维细胞生长因子23基因多态性与慢性心力衰竭患者预后的相关性研究[J]. 现代检验医学杂志,2020,35(1):35-39. SU Hong，LI Shilin，WANG Changyu，et al. Association of fibroblast growth factors 23 gene polymorphism and prognosis in patients with chronic heart failure [J]. Journal of Modern Laboratory Medicine, 2020, 35(1): 35-39.
[6] BOUZINA H, HESSELSTRAND R, R?DEGRAN G. Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension[J]. Pulmonary Circulation, 2019, 9(4):2045894019895446.
[7] WIDMANN L, KERANOV S, JAFARI L, et al. Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension[J]. Clinical Research in Cardiology, 2023, 112(10): 1382-1393.
[8] SAHIN A, KAYA H, AVCI O. Cancer antigen-125 is a predictor of mortality in patients with pulmonary arterial hypertension [J]. Clinical Biochemistry, 2020, 89: 58-62.
[9] ZHANG Yi, JIN Qi, ZHAO Zhihui, et al. Carbohydrate antigen 125 is a biomarker of the severity and prognosis of pulmonary hypertension [J]. Frontiers in Cardiovascular Medicine, 2021, 8: 699904.
[10] BANASZKIEWICZ M, PIETRASIK A, DAROCHA S, et al. Soluble ST2 protein as a new biomarker in patientswith precapillary pulmonary hypertension[J]. Archives of Medical Science, 2020(1).DOI:10.5114/AOMS.2020.98635.
[11] 李全双, 许靖, 吴燕, 等. 朗道血清质控品作为ELISA法检测血清可溶性ST2室内质控物的可行性探讨[J].现代检验医学杂志, 2022,37(5):190-193． LI Quanshuang, XU Jing, WU Yan, et al. Feasibility study on randox serum quality control products as elisa method to detect serum soluble ST2 internal quality control materials[J]. Journal of Modern Laboratory Medicine, 2022, 37(5): 190-193.
[12] GEENEN L W, BAGGEN V J M, KAULING R M, et al. The prognostic value of soluble ST2 in adults with pulmonary hypertension[J]. Journal of Clinical Medicine, 2019, 8(10): 1517.
[13] SUN Yuanyuan, WANG Lan, MENG Xiangrui, et al. Soluble ST2 and mixed venous Oxygen saturation for prediction of mortality in patients with pulmonary hypertension[J]. Journal of Thoracic Disease, 2021, 13(6): 3478-3488.
[14] BANASZKIEWICZ M, PIETRASIK A, FLORCZYK M, et al. Soluble ST2 as a biomarker for early complications in patients with chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty[J]. Diagnostics Basel Switzerland, 2021, 11(1): 133.
[15] 李超，朱晓丹，张玲华，等．基于GEO 数据库整合miRNA-mRNA 表达谱筛选卵巢癌的关键基因分子及生物信息分析[J]．现代检验医学杂志，2021，36（5）：38-42． LI Chao, ZHU Xiaodan, ZHANG Linghua, et al. Screening key biomarkers and bioinformatic analysis of ovarian cancer byintegrated mirna-mrna expression profiles based on geo database[J]. Journal of Modern Laboratory Medicine, 2021, 36(5): 38-42.
[16] PULL AMSETTI S S, DOEBELE C, FISCHER A, et al. Inhibition of microRNA-17 inproves lung adn heart function in experimental pulmonary hypertension [J]. American Journal of Respiratory and Critical Care Medicine,2012,185(4):409-419.
[17] ZHANG Wei, QI Yujuan, WU Bo. MicroRNA-146-5p promotes pulmonary artery endothelial cell proliferation under hypoxic conditions through regulating USP3 [J]. Disease Markers, 2021, 2021:3668422.
[18] D?ZG?N Z, KAYIK?IOGLU L M, AKTAN ?, et al. Decreased circulating microRNA-21 and microRNA-143 are associated to pulmonary hypertension[J]. Turkish Journal of Medical Sciences, 2023, 53(1): 130-141.
[19] YUE Yuxia, ZHANG Zhiyong, ZHANG Lei, et al. MiR-143 and miR-145 promote hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells through regulating ABCA1 expression [J]. Cardiovascular Pathology, 2018,37:15-25.
[20] JIN Peng, GU Wenzhu, LAI Yayu, et al. The circulating microRNA-206 level predicts the severity of pulmonary hypertension in patients with left heart diseases[J]. Cellular Physiology and Biochemistry, 2017, 41(6): 2150-2160.
[21] JALALI S, RAMANATHAN G K, PARTHASARATHY P T, et al. MiR-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation[J]. PLoS One, 2012, 7(10): e46808.
[22] ZHAO Hui, DUAN Ruowang, WANG Qian, et al. MiR-122-5p as a potential regulator of pulmonary vascular wall cell in idiopathic pulmonary arterial hypertension[J]. Heliyon, 2023, 9(12): e22922.
[23] WANG Meibin, SU Lihuang, SUN Junwei, et al. FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ[J]. Journal of Cellular and Molecular Medicine, 2022, 26(4): 1034-1049.
[24] TAN Hong, YAO Hua, LIE Zhenbang, et al. MicroRNA-30a-5p promotes proliferation and inhibits apoptosis of human pulmonary artery endothelial cells under hypoxia by targeting YKL-40 [J]. Molecular Medicine Reports, 2019, 20(1): 236-244.
[25] CONNOLLY M, GARFIELD B E, CROSBY A, et al. MiR-1-5p targets TGF-βR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension[J]. PLoS One, 2020, 15(2): e0229409.
[26] WANG Jingjing, JIANG Rong, TAN Yanlin, et al. Human pulmonary artery smooth muscle cell dysfunction is regulated by miR-509-5p in hypoxic environment[J]. Cell Cycle, 2022, 21(11): 1212-1221.
[27] ZHANG Shuai, YANG Ting, XU Xiaomao, et al. Oxidative stress and nitric oxide signaling related biomarkers in patients with pulmonary hypertension: a case control study [J]. BMC Pulmonary Medicine, 2015, 15: 50.
[28] PARMAKSIZ E T, INAL A, SALEPCI B, et al. Relationship of asymmetric dimethylarginine levels with disease severity and pulmonary hypertension in chronic obstructive pulmonary disease[J]. Lung India, 2018, 35(3): 199-203.
[29] PARIKH R V, SCHERZER R, NITTA E M, et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection[J]. AIDS, 2014, 28(4): 511-519.
[30] THAKKAR V, STEVENS W, PRIOR D, et al. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosisrelated pulmonary arterial hypertension: a case control study[J]. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100(5): 129-136.
[31] T?RER CABBAR A, DE?ERTEKIN M M, ?IM?EK M A, et al. Evaluation of asymmetric dimethylarginine levels in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy[J]. Heart Lung and Circulation, 2022, 31(1): 110-118.
[32] RYANTO G R T, IKEDA K, MIYAGAWA K, et al. An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension[J]. Nature Communications, 2021, 12(1): 1720.
[33] GUIGNABERT C, SAVALE L, BOUCLY A, et al. Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension[J]. Circulation, 2023, 147(24): 1809-1822.
[34] HADWIONO M R, HARTOPO A B, WASITYASTUTI W, et al. Increased serum activin A level in congenital heart disease-associated pulmonary artery hypertension: A comparative study from the COHARD-PH registry[J]. Pulmonary Circulation, 2023, 13(3): e12280.
[35] CHANG Weiting, SHIH J Y, LIN Yuwen, et al. Growth differentiation factor-15 levels in the blood around the pulmonary artery is associated with hospitalization for heart failure in patients with pulmonary arterial hypertension[J]. Pulmonary Circulation, 2020, 10(4): 2045894020962948.
[36] QIAN Junyan, DING Yufang, YANG Xiaoxi, et al. The diagnostic and prognostic value of growth differentiation factor-15 in systemic lupus erythematosus-associated pulmonary arterial hypertension[J]. Pulmonary Circulation, 2023, 13(1): e12195.
[37] MAIMAITI Y,CHENG Hui, GUO Zitong, et al. Correlation between serum GDF-15 level and pulmonary vascular morphological changes and prognosis in patients with pulmonary arterial hypertension[J]. Frontiers in Cardiovascular Medicine, 2023, 10: 1085122.
[38] KRIECHBAUM S D, WIEDENROTH C B, PETERS K, et al. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension[J]. Biomarkers, 2020, 25(7): 578-586.
[39] MIRNA M, ROHM I, JIRAK P, et al. Analysis of novel cardiovascular biomarkers in patients with pulmonary hypertension (PH)[J]. Heart Lung and Circulation, 2020, 29(3): 337-344.
[40] 王勇, 张克波. 老年心力衰竭患者血清NF-κB,Gal-3和sST2 水平联合检测与预后评估价值[J]. 现代检验医学杂志，2022,37(5): 148-153. WANG Yong, ZHANG Kebo. Prognostic value of combined serum NF-κB, Gal-3 and sST2 levels in elderly patients with heart failure[J]. Journal of Modern Laboratory Medicine, 2022, 37(5): 148-153.
[41] SHEN Qiang, CHEN Wei, LIU Jun, et al. Galectin-3 aggravates pulmonary arterial hypertension via immunomodulation in congenital heart disease [J]. Life Sciences, 2019, 232: 116546.
[42] GEENEN L W, BAGGEN V J M, KOUDSTAAL T, et al. The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach [J]. American Heart Journal, 2019, 208: 91-99.
[43] ZHANG Zejian, WANG Huifang, LIAN Tianyu, et al. Human plasma IgG N-Glycome profiles reveal a proinflammatory phenotype in chronic thromboembolic pulmonary hypertension[J]. Hypertension, 2023, 80(9): 1929-1939.
[44] HUANG Jing, AN Qi, ZHANG Cailian, et al. Decreased low-density lipoprotein and the presence of pulmonary arterial hypertension among newly diagnosed drug-na?ve patients with systemic lupus erythematosus: D-dimer as a mediator[J]. Experimental and Therapeutic Medicine, 2022, 24(3): 595.
[45] ARUNTHARI V, BURGER C D. Utility of D-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension [J]. the Open Respiratory Medicine Journal, 2009, 3: 85-89.
[46] AHMED A, AHMED S, R?DEGRAN G. Plasma ADAMTS13 and von willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension[J]. Pulmonary Circulation, 2021, 11(4): 20458940211041500.
[47] MANZ X D, SZULCEK R, PAN Xiaoke, et al. Epigenetic modification of the von willebrand factor promoter drives platelet aggregation on the pulmonary endothelium in chronic thromboembolic pulmonary hypertension[J]. American Journal of Respiratory and Critical Care Medicine, 2022, 205(7): 806-818.
[48] MARTENS P, YU Shilin, LARIVE B, et al. Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications[J]. European Heart Journal, 2023, 44(22): 1979-1991.
相似文献/References:
[1]夏 芳a,汪隆海a,方 超a,等.血清5种生物标志物水平联合检测对心力衰竭的诊断价值[J].现代检验医学杂志,2019,34(04):22.[doi:10.3969/j.issn.1671-7414.2019.04.006]
XIA Fanga,WANG Long-haia,FANG Chaoa,et al.Combined Detection of Serum 5 Biomarkers
for the Diagnostic Value of Heart Failure[J].Journal of Modern Laboratory Medicine,2019,34(01):22.[doi:10.3969/j.issn.1671-7414.2019.04.006]
[2]李泽东,詹 贞,刘 忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(01):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
[3]樊春荔,何燕娟.缺血性脑卒中和短暂性脑缺血发作患者血清miR-23b-3p 水平变化的比较研究[J].现代检验医学杂志,2020,35(05):51.[doi:10.3969/j.issn.1671-7414.2020.05.013]
FAN Chun-li,HE Yan-juan.Altered Levels of Serum miR-23b-3p in Patients with Ischemic Stroke and
Transient Ischemic Attack[J].Journal of Modern Laboratory Medicine,2020,35(01):51.[doi:10.3969/j.issn.1671-7414.2020.05.013]
[4]潘锡龙,陈 丽,梁利斯.基于Logistic 回归和 ROC 曲线评价外周血 PCT，CRP，NEU% 和 PLT 水平在血流感染中的联合预测价值[J].现代检验医学杂志,2020,35(06):119.[doi:doi:10.3969/j.issn.1671-7414.2020.06.029]
PAN Xi-long,CHEN Li,LIANG Li-si.Evaluation of the Combined Predictive Value of Peripheral Blood PCT, CRP,NEU% and PLT Levels in Bloodstream Infection Based onLogistic Regression and ROC Curve[J].Journal of Modern Laboratory Medicine,2020,35(01):119.[doi:doi:10.3969/j.issn.1671-7414.2020.06.029]
[5]王 苗,张 萍.COPD患者血清 Cav-1及 CXCL12水平检测与并发肺动脉高压的相关性研究[J].现代检验医学杂志,2021,36(01):29.[doi:10.3969/j.issn.1671-7414.2021.01.008]
WANG Miao,ZHANG Ping.Correlation between Levels of Cav-1 and CXCL12 in Serum and Pulmonary Hypertension in Patients with COPD[J].Journal of Modern Laboratory Medicine,2021,36(01):29.[doi:10.3969/j.issn.1671-7414.2021.01.008]
[6]苏 虹a,王文利b,王 东a,等.冠心病患者血液hs-CRP，ET-1，NO，NT-ProBNP及D-D水平联合检测在评估左心衰竭并发肺动脉高压的临床价值[J].现代检验医学杂志,2021,36(04):147.[doi:10.3969/j.issn.1671-7414.2021.04.032]
SU Honga,WANG Wen-lib,WANG Donga,et al.Clinical Value of Combined Detection of Serum hs-CRP, ET-1, NO, NT-proBNP and D-D Levels in Patients with Coronary Heart Disease in EvaluatingLeft Heart Failure Complicated with Pulmonary Hypertension[J].Journal of Modern Laboratory Medicine,2021,36(01):147.[doi:10.3969/j.issn.1671-7414.2021.04.032]
[7]王欣俞a,赵晋文a,蔡立文a,等.基于核磁共振氢谱筛选隐性梅毒患者血清代谢组学生物标志物的研究[J].现代检验医学杂志,2021,36(05):46.[doi:10.3969/j.issn.1671-7414.2021.05.010]
WANG Xin-yua,ZHAO Jin-wena,CAI Li-wena,et al.Study on Screening of Metabolomic Biomarkers in Recessive SyphilisPatients Based on 1H NMR[J].Journal of Modern Laboratory Medicine,2021,36(01):46.[doi:10.3969/j.issn.1671-7414.2021.05.010]
[8]徐海燕,陆学东.多发性骨髓瘤早期实验诊断相关新兴生物标志物的最新研究进展[J].现代检验医学杂志,2021,36(05):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
XU Hai-yan,LU Xue-dong.Recent Research Rrogress of Novel Biomarkers for Early ExperimentalDiagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(01):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
[9]吴良银a,李文丽b,刘 俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(01):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[10]宋秀军,卢敬泰,牛冬梅,等.X射线照射对人外周血淋巴细胞 miRNA表达谱影响的初步研究[J].现代检验医学杂志,2022,37(01):159.[doi:10.3969/j.issn.1671-7414.2022.01.032]
SONG Xiu-jun,LU Jing-tai,NIU Dong-mei,et al.Preliminary Study on miRNA Expression Profile of Human Peripheral Blood Lymphocytes Irradiated by X-ray[J].Journal of Modern Laboratory Medicine,2022,37(01):159.[doi:10.3969/j.issn.1671-7414.2022.01.032]